There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Catalyst Pharma (NASDAQ:CPRX) and Opiant Pharmaceuticals Inc (NASDAQ:OPNT) with bullish sentiments.
Catalyst Pharma (CPRX)
In a report released today, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Catalyst Pharma, with a price target of $8. The company’s shares opened today at $3.58.
Duncan commented:
“We rate CPRX Overweight. Catalyst’s lead candidate Firdapse has a PDUFA date of 11/28/18 for LEMS for which we think it will be approved, conveying 7-year orphan exclusivity. Approval would clear an overhang & end investor debate over private co. Jacobus beating Catalyst in the race for 1st orphan approval, in our view. We guesstimate >300 LEMS patients are already on 3,4 DAP or Firdapse due to investigator-sponsored INDs (3,4 DAP) or EAP (Firdapse). Catalyst needs The Disclosure Section may be found on pages 4 – 5.to successfully transition “free” & EAP patients in the commercial setting to further enhance conviction on the drug’s clinical value & potential.”
According to TipRanks.com, Duncan is a 3-star analyst with an average return of 3.0% and a 48.1% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Catalyst Pharma with a $6.80 average price target.
See today’s analyst top recommended stocks >>
Opiant Pharmaceuticals Inc (OPNT)
In a report released today, Brandon Folkes from Cantor Fitzgerald reiterated a Buy rating on Opiant Pharmaceuticals Inc, with a price target of $42. The company’s shares opened today at $17.91, close to its 52-week low of $12.75.
Folkes noted:
“We reiterate our OW rating on Opiant, which is developing treatments focused on multiple addictions as well as a new product for opioid overdose. As the company advances its pipeline, and provided the data are positive, which we believe they should be, we expect investors to begin to appreciate the market potential of Opiant’s pipeline, and that should drive the stock higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $42 price target.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.5% and a 41.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.
Opiant Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $42.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
